eClinical Technology and Industy News

Tenon(R) Medical Announces Positive Fusion Results in First Patients Reaching 12-Month Follow Up in an IRB Approved, Multi-Centered, Post-Market Study Utilizing the Catamaran(R) SI Joint Fusion System

Preliminary SI Joint Fusion Results Based on Independent Radiologist Review Indicate Robust Fusion at 12-Months Post-Procedure
Initial Patient Results Demonstrate Marked Improvements in Pain Scores and Disability, Along with High Patient Satisfaction Ratings

Excerpt from the Press Release:

LOS GATOS, CA / ACCESSWIRE / March 26, 2024 / Tenon Medical, Inc. (NASDAQ:TNON) (“Tenon” or the “Company”), a company transforming care for patients suffering with certain sacroiliac joint disorders, today announced significant progress in the post-market study utilizing the Company’s Catamaran® SI Joint Fusion System. The study is a prospective, multi-center, single-arm post market study evaluating the clinical outcomes of patients with sacroiliac joint disruptions or degenerative sacroiliitis treated with the Catamaran SI Joint Fusion System. Patients will be evaluated for a period of up to 24 months reviewing various patient reported outcomes, radiographic assessments, and adverse events. Study enrollment is expected to be finalized in the coming quarter.

The preliminary results demonstrate a robust fusion response at 12-months post-procedure based on the independent radiologist review of computed tomography (CT) scans of the SI joint in 100% of the initial cohort of treated patients that have reached the 12-month follow-up. Additionally, these initial results demonstrate marked improvements in pain scores and disability. These preliminary results also reflect high patient satisfaction ratings specific to the procedure and outcomes.

Timothy Beacham, MD, FASA, Interventional Pain physician at Restorative Pain Institute in Louisville, KY and study investigator, commented, “I am extremely pleased with my patient outcomes as it pertains to reduction in pain symptoms and positive patient satisfaction utilizing the Catamaran implant. Equally impressive is that there is definitive CT imaging of all initial study patients showing unequivocal fusion at the 12-month follow-up period. If this outcome remains consistent across the study population, Tenon Medical’s Catamaran implant represents a considerable differentiating factor to advance the treatment of SI joint disease.”

Click the button below to read the entire Press Release:

Continue Reading The Press Release

Discover What Sets TrialStat Apart From Ordinary EDC Platforms

Click the image or button below to explore our eClinical Suite Platform and discover what sets TrialStat apart from competing EDC platforms.

Request Your Demo Today!

From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?